Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp

In the 1990s, monoclonal antibodies (mAbs) progressed from scientific tools to advanced therapeutics, particularly for the treatment of cancers and autoimmune and inflammatory disorders. In the arena of infectious disease, the inauguration of mAbs as a post-exposure treatment in humans against Ebola...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antiviral research Jg. 226; S. 105873
Hauptverfasser:	Wong, Gary, Bienes, Kathrina Mae, XIII, Ara, Fausther-Bovendo, Hugues, Kobinger, Gary P.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Netherlands Elsevier B.V 01.06.2024
Schlagworte:	Africa, Western - epidemiology Animals Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use Antibodies, Neutralizing - immunology Antibodies, Neutralizing - therapeutic use Antibodies, Viral - immunology Antibodies, Viral - therapeutic use Disease Outbreaks Ebola Virus Ebolavirus - drug effects Ebolavirus - immunology EBOV Hemorrhagic Fever, Ebola - drug therapy Hemorrhagic Fever, Ebola - immunology Humans mAbs Monoclonal antibodies ZMapp Africa, Western Monoclonal antibodies EBOV Ebola Virus ZMapp mAbs
ISSN:	0166-3542, 1872-9096, 1872-9096
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!